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Introduction: The aim of this study was to characterize the association of human leukocyte antigen (HLA) B alleles
and major histocompatibility complex (MHC) single nucleotide polymorphisms (SNPs) with Behçet’s disease (BD) in
an Iranian dataset.
Methods: The association of three SNPs in the MHC region previously identified as the most associated in high-density
genotyping studies was tested in a case–control study on 973 BD patients and 825 controls from Iran, and the
association of HLA-B alleles was tested in a subset of 681 patients and 414 controls.
Results: We found that HLA-B*51 (P = 4.11 × 10−41, OR [95% CI] = 4.63[3.66-5.85]) and B*15 confer risk for BD
(P = 2.83 × 10−2, OR [95% CI] = 1.75[1.08-2.84]) in Iranian, and in B*51 negative individuals, only the B*15 allele is
significantly associated with BD (P = 2.51 × 10−3, OR [95% CI] = 2.40[1.37-4.20]). rs76546355, formerly known as
rs116799036, located between HLA-B and MICA (MHC class I polypeptide-related sequence A), demonstrated the
same level of association with BD as HLA-B*51 (Padj = 1.78 × 10
−46, OR [95% CI] = 5.46[4.21-7.09], and Padj = 8.34 ×
10−48, OR [95% CI] = 5.44[4.20-7.05], respectively) in the HLA-B allelotyped subset, while rs2848713 was less associated
(Padj = 7.14 × 10
−35, OR [95% CI] = 3.73[2.97-4.69]) and rs9260997 was not associated (Padj = 1.00 × 10
−1). Additionally,
we found that B*51 genotype-phenotype correlations do not survive Bonferroni correction, while carriers of the
rs76546355 risk allele predominate in BD cases with genital ulcers, positive pathergy test and positive BD family
history (2.31 × 10−4 ≤ P ≤ 1.59 × 10−3).
Conclusions: We found that the HLA-B*51 allele and the rs76546355/rs116799036 MHC SNP are independent
genetic risk factors for BD in Iranian, and that positivity for the rs76546355/rs116799036 risk allele, but not for B*51,
does correlate with specific demographic characteristics or clinical manifestations in BD patients.Introduction
Behçet’s disease (BD) is a systemic immuno-inflammatory
disorder classified as a vasculitis and affects blood vessels of
nearly all sizes and types, especially in the mucocutaneous
and ocular structures. The most common manifestations
are recurrent orogenital ulcerations and ophthalmologic
inflammatory lesions, but may also involve the vascular,* Correspondence: aaoliveira@medicina.ulisboa.pt
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tems. The etiopathology of BD remains uncertain, but in-
fectious or environmental factors are thought to trigger an
excessive immune and/or inflammatory response in genet-
ically predisposed individuals.
The human leukocyte antigen class I allele HLA-B*51
is a well-established and universal genetic risk factor for
BD, but the susceptibility conferred by other HLA-B al-
leles such as B*15 or B*35 remains controversial [1,2].
Additionally, recent genome-wide association studies
(GWAS) and in-depth investigations of the major histo-
compatibility complex (MHC) region have suggestedThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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ample, HLA-A*26, HLA-Cw*1602) and of other SNPs or
genes located in the MHC locus (for example,
PSORS1C1) [3-7]. However, these reports have also been
inconsistent, have not been validated by independent re-
search groups, and have not systematically addressed
whether an SNP or an HLA allele is the strongest risk
factor for BD. Furthermore, numerous small studies
have investigated genotype-phenotype correlations in BD
patients (reviewed and meta-analyzed in Maldini et al.
[8]), but well-powered studies exploring the association
of risk genotypes with all the major clinical and demo-
graphic characteristics of BD cases are lacking.
In this context, the aim of this study was to better
characterize the risk conferred by HLA-B alleles and MHC
SNPs for Behçet’s disease in an Iranian dataset and to test if
there is a correlation between the genotypes at the stron-
gest genetic risk factors and characteristics of BD patients.
Methods
Study subjects
The study participants were enrolled in the Behçet’s dis-
ease outpatient clinic, Rheumatology Research Center,
Shariati Hospital, at the Tehran University of Medical
Sciences, Tehran, Iran from 2007 to 2012. The diagnosis
of BD was made according to the revised International
Criteria for Behçet’s Disease [9]. Patients with age at on-
set of BD after 60 years were excluded. Controls were
evaluated using the same evaluation procedures as the
cases and selected when negative for BD, any other
rheumatological or auto-immune disorder and oral
aphthosis. The clinical and demographic features of the




Male gender, n/total n (%) 511/973 (52.5)
Age at examination, years, mean ± SD 39.1 ± 10.9
Age at onset, years, mean ± SD 26.0 ± 9.6
Oral aphthosis, n/total n (%) 962/973 (98.9)
Genital aphthosis, n/total n (%) 609/973 (62.6)
Skin lesions, n/total n (%) 539/973 (55.4)
Ophthalmologic manifestations, n/total n (%) 583/973 (59.9)
Joint manifestations, n/total n (%) 300/973 (30.8)
Neurological manifestations, n/total n (%) 61/973 (6.3)
Vascular involvement, n/total n (%)) 51/973 (5.2)
Gastrointestinal manifestations, n/total n (%) 38/973 (3.9)
Pathergy phenomenon, n/total n (%) 441/959 (46.0)
Family history of BD, n/total n (%) 85/935 (9.1)
n/total n = number of individuals/total number of cases or controls analysed.time of blood sampling and inspection of medical records.
The clinical characteristics described in Table 1 are de-
fined as follows: skin lesions include pseudo folliculitis,
erythema nodosum, and skin aphthosis; ophthalmologic
manifestations refer to anterior uveitis, posterior uveitis,
and retinal vasculitis; joint manifestations include arthral-
gia, arthritis, and ankylosing spondylitis; neurological
manifestations include peripheral and central manifesta-
tions; vascular involvement refers to arterial thrombosis,
large vein thrombosis, phlebitis, and superficial phle-
bitis; gastrointestinal manifestations include chronic
diarrhea and proctorrhagia. Even though approximately
9% of the cases and controls have a family history of BD,
all cases and controls are not known to be genetically
related.
This study received ethical approval from the ethics
committee at the Tehran University for Medical Sci-
ences, Iran. All participants were informed of the study,
provided informed written consent and the study was
conducted according to the Declaration of Helsinki.
HLA-B class I typing
Blood samples were drawn into EDTA tubes and stored at
−20°C until genomic DNA was extracted using QIAamp®
DNA Blood Maxi kits (QIAGEN, Hilden, Germany) or a
salting out procedure and diluted in Tris-EDTA buffer.
The concentrations of extracted DNA were determined by
Nanodrop using absorbance readings at 260 nm and the
DNA was then stored at 4°C.
A random subset (681 BD cases and 414 controls) of
the total dataset was typed for HLA-B with a
hybridization bead-based array using reverse-sequence




348/825 (42.2) 480/681 (70.5) 281/414 (67.9)
40.5 ± 11.9 39.2 ± 10.6 42.7 ± 11.5
26.0 ± 9.5
0/825 (0.0) 672/681 (98.7) 0/414 (0.0)
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were performed at the Lisbon Center for Blood and
Transplantation (Lisboa, Portugal) with lot#11 of LAB-
Type RSSO1B reagents (One Lambda, Canoga Park, CA,
USA) according to manufacturer instructions.
Genotyping
Individual samples were genotyped in the Genomics Unit of
the Instituto Gulbenkian de Ciência (Oeiras, Portugal) using
the Sequenom iPlex assay (San Diego, CA, USA), according
to the manufacturer’s protocol, and detected in a Sequenom
MassArray K2 platform. The primer sequences (Additional
file 1: Table S1) were designed using the Sequenom Mass-
Array Assay Design V.3.0 software. Extensive quality control
was performed using eight HapMap [10] controls of diverse
ethnic affiliations, sample duplication within and across
plates, Mendelian inheritance check in three large pedigrees
(used for quality control purposes only), Hardy-Weinberg
equilibrium (HWE) in the control group (P >0.001), and a
call rate for each SNP >90%. Genotype determinations were
performed blinded to affection status (control or case).
Individual DNA samples with genotyping success rate across
all SNPs <85% were also excluded.
Association analysis
The unpaired Student’s t-test and the chi-square (χ2) test
was used to compare quantitative and qualitative clinical
and demographic data between BD cases and controls, re-
spectively. SNP association analysis, unadjusted and adjusted
for gender and pairwise conditional analysis, was performed
with logistic regression using the SNPassoc V.1.4-9 package
[11] implemented in R [12]. The χ2 tests were performed to
explore the association of each HLA-B allele with BD (each
allele was compared with all other alleles pooled together)
and to test the association of HLA-B*51 and the A allele of
rs76546355/rs116799036 to BD cases clinical features. The
χ2 test for Hardy-Weinberg equilibrium in controls and
linkage disequilibrium (LD) calculation was performed using
Haploview 4.2 [13]. The odds ratio (OR) and associated 95%
CI was calculated for SNPs with significant associations with
BD. Nominal significance (P ≤5.00 × 10−2) was used to de-
clare an association significant in the association analysis of
the HLA-B alleles with BD (as the tests performed are not
independent), and in the association of SNPs with BD (as
these constitute replications of previously reported associa-
tions). For the association of clinical manifestations in BD
patients with genetic variants, results were declared signifi-
cant below the Bonferroni correction level (P ≤4.17 × 10−3
for 12 tested characteristics).
Results
Dataset characterization
The main clinical and demographic characteristics of the
973 BD cases and 824 controls used in the SNPassociation study are summarized in Table 1. The distri-
bution of clinical symptoms in the Iranian BD patients
(for example, 98.9% with oral aphthosis, 62.6% with
genital aphthosis, 59.9% with ophthalmological manifes-
tations) is in line with observations for larger datasets
[9,14], but skin lesions (55.4%) and gastrointestinal man-
ifestations (3.9%) are less frequent than previously re-
ported in Iranians (64.9% to 73.6% and 7.4% to 8.8%,
respectively) [15-17]. The average age at examination
(AAE) was slightly higher in controls when compared to
BD cases (mean AAE ± SD of 39.1 ± 10.9 years in BD
and 40.5 ± 11.9 years in controls, P = 1.16 × 10−2) but this
nominally significant difference did not withstand
Bonferroni correction for all the clinical variables tested.
Male-to-female ratio was increased in BD patients (P =
1.23 × 10−5). As the percentage of males has been re-
ported to influence the strength of association between
HLA-B*51 and BD [18] and may also influence the asso-
ciation of genetic variants in the HLA-B region, gender
was included as a covariate in adjusted logistic regres-
sion models of association.
BD cases (n = 681) and controls (n = 414) randomly se-
lected from our total BD dataset were allelotyped for
HLA-B. The characteristics of this smaller group of indi-
viduals are similar to those of the full dataset with the
exception of the male gender, which is more prevalent in
the HLA-B allelotyped dataset (Table 1).
Association of HLA-B alleles with BD risk
To investigate the association of HLA-B alleles with BD
in the Iranian population, we first allelotyped HLA-B in
681 BD cases and 414 controls. Among the 31 observed
HLA-B alleles, 14 had frequencies ≤2% in controls
(alleles B*58, B*37, B*39, B*57, B*53, B*42, B*73, B*45,
B*47, B*56, B*46, B*48, B*54, B*67) and were pooled to-
gether in Table 2. The association of the remaining 17
HLA-B alleles with BD susceptibility was then assessed
individually by testing each allele against all others
pooled together.
The HLA-B*51 genotype distribution (and frequencies)
were the following: 79 (11.6%) patients were homozy-
gotes (B*51/B*51), 375 (55.1%) were heterozygotes
(B*51/any other HLA-B allele), and 227 (33.3%) did not
have any B*51 allele; 9 (2.2%) controls were homozygous
for B*51, 82 (19.8%) were heterozygous for B*51, and
323 (78.0%) were not carriers of B*51. Therefore, in our
dataset, the B*51 allele frequency was 39.1% in cases and
12.1% in controls (Table 2), and 66.7% of cases and
22.0% of controls were B*51-positive (B*51/B*51 homo-
zygotes plus B*51 heterozygotes). As expected, the HLA-
B*51 allele significantly increased the BD risk (P = 4.11 ×
10−41, OR (95% CI) = 4.63 (3.66, 5.85)). Even though to a
lesser degree, HLA-B*15 also appeared to confer risk for
BD (P = 2.83 × 10−2, OR (95% CI) = 1.75 (1.08 to 2.84)).
Table 2 HLA-B allele frequencies and their association with Behçet’s disease (BD)
HLA-B allelotyped dataset HLA-B*51 negative individuals
HLA-B allele Cases Controls P-values Odds ratio Cases Controls P-values Odds ratio
(95% CI) (95% CI)
B*35 13.2% 22.0% 1.19 × 10−7 0.54 (0.43, 0.68) 22.2% 25.3% 2.72 × 10−1
B*51 39.1% 12.1% 4.11 × 10−41 4.63 (3.66, 5.85) - - -
B*52 3.0% 5.8% 1.99 × 10−3 0.50 (0.33, 0.77) 5.3% 6.5% 4.72 × 10−1
B*18 4.2% 5.7% 1.37 × 10−1 7.5% 6.7% 6.90 × 10−1
B*07 2.8% 5.0% 1.20 × 10−2 0.55 (0.35, 0.86) 4.2% 5.6% 3.62 × 10−1
B*13 2.2% 4.1% 1.49 × 10−2 0.53 (0.32, 0.87) 3.7% 4.7% 5.58 × 10−1
B*08 2.5% 4.0% 6.66 × 10−2 3.3% 4.2% 5.51 × 10−1
B*38 3.3% 3.9% 5.68 × 10−1 7.0% 4.8% 1.51 × 10−1
B*55 3.7% 3.9% 9.08 × 10−1 5.3% 4.3% 5.64 × 10−1
B*40 1.6% 3.7% 2.70 × 10−3 0.42 (0.24, 0.73) 2.2% 4.0% 1.31 × 10−1
B*44 3.4% 3.7% 8.10 × 10−1 5.9% 4.2% 2.37 × 10−1
B*41 2.3% 3.5% 1.16 × 10−1 2.9% 4.2% 3.20 × 10−1
B*50 2.6% 3.5% 2.60 × 10−1 5.1% 3.7% 3.53 × 10−1
B*14 2.0% 3.1% 1.17 × 10−1 2.9% 3.6% 6.34 × 10−1
B*49 1.5% 3.0% 2.89 × 10−2 0.50 (0.28, 0.90) 1.8% 3.4% 1.42 × 10−1
B*15 4.8% 2.8% 2.83 × 10−2 1.75 (1.08, 2.84) 7.5% 3.3% 2.51 × 10−3 2.40 (1.37, 4.20)
B*27 2.6% 2.5% 9.27 × 10−1 4.8% 2.8% 1.05 × 10−1
Other 5.2% 7.6% 8.4% 8.7%
The complete dataset allelotyped for human leukocyte antigen (HLA)-B includes 681 BD cases and 414 controls, and the subset of HLA-B*51-negative individuals
is composed of 227 BD cases and 323 controls. Other (first column) includes alleles with a frequency ≤2.0% in the control group. Nominally significant P-values
are highlighted in bold and the respective odds ratio and 95% CI are indicated.
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alleles seemed to be protective (1.19 × 10−7 ≤ P ≤2.89 ×
10−2) (Table 2).
AS the strong difference in HLA-B*51 allele frequen-
cies between cases and controls may secondarily and ar-
tificially affect or mask the association of the other
alleles, we performed case-control association tests in
the subset of samples negative for B*51. We tested their
association in the 227 BD cases (33.3%) and 323 controls
(78.0%) who were not carriers of the B*51 allele. In this
group of individuals, only the B*15 allele remained sig-
nificantly associated (P = 2.51 × 10−3, OR (95% CI) = 2.40
(1.37, 4.20)) with BD (Table 2).
Association of MHC SNPs with BD risk
To confirm the previously described associations with
BD of polymorphisms in the MHC locus and to compare
them with the HLA-B*51 association in an Iranian sam-
ple, we selected the top four MHC SNPs identified in
GWAS conducted on Japanese, Chinese and Turkish
samples (rs4959053 from Mizuki et al. [19] and Hou et
al. [5], rs9260997 and rs2848713 from Remmers et al.
[4], and rs4947296 from Lee et al. [6]) and the top SNP
(rs116799036, currently known as rs76546355) identified
on a recent and exhaustive study of the MHC locus inItalian and Turkish BD cases and controls [7]. The
rs4947296 SNP failed in the assay design phase and the
rs4959053 SNP did not pass the HWE quality control
check (P = 8.00 × 10−4 in the control samples), and there-
fore their association with BD was not assessed.
The association results of these three polymorphisms are
shown in Table 3. rs9260997 in the HLA-G/H/J gene was
nominally associated with BD in the full dataset (Padj =
2.20 × 10−2, OR (95% CI) = 1.31 (1.04, 1.67)) but not in
the subset allelotyped for HLA-B (Padj = 1.00 × 10
−1).
rs76546355/rs116799036, located between HLA-B and
MICA, and rs2848713, located downstream of MICA,
were both strongly associated with BD in the full dataset
(Padj = 9.34 × 10
−68, OR (95% CI) = 4.56 (3.78 to 5.50), and
Padj = 4.90 × 10
−55, OR (95% CI) = 3.52 (2.97, 4.18), re-
spectively). In the HLA-B typed subset, the association
of rs76546355/rs116799036 (Padj = 1.78 × 10
−46, OR (95%
CI) = 5.46 (4.21, 7.09)) was similar to that of HLA-B*51
(Padj = 8.34 × 10
−48, OR (95% CI) = 5.44 (4.20, 7.05)) and
stronger than that of rs2848713 (Padj = 7.14 × 10
−35, OR
(95% CI) = 3.73 (2.97, 4.69)).
To determine if the associations of rs76546355/
rs116799036, rs2848713, and HLA-B*51 are independent,
we performed pairwise conditional logistic regression ana-
lyses (Table 4). Except for the association of rs2848713
Table 3 Association between MHC single nucleotide polymorphisms (SNP) and Behçet’s disease in the full dataset and
on the subset allelotyped for HLA-B
Dataset dbSNP ID Gene or Allele Frequency Punadj-values Padj-values Odds ratio (95% CI)
nearest gene Cases Controls
Total rs9260997 HLA-G/H/J C 0.911 0.886 2.03 × 10−2 2.20 × 10−2 1.31 (1.04, 1.67)
rs76546355 HLA, B - MICA A 0.388 0.140 2.51 × 10−69 9.34 × 10−68 4.56 (3.78, 5.50)
rs2848713 MICA A 0.422 0.184 2.12 × 10−56 4.90 × 10−55 3.52 (2.97, 4.18)
HLA-B allelotyped rs9260997 HLA-G/H/J C 0.908 0.886 1.06 × 10−1 1.00 × 10−1
rs76546355 HLA-B - MICA A 0.388 0.126 9.84 × 10−47 1.78 × 10−46 5.46 (4.21, 7.09)
rs2848713 MICA A 0.427 0.184 4.83 × 10−35 7.14 × 10−35 3.73 (2.97, 4.69)
HLA-B B*51 0.391 0.121 5.86 × 10−48 8.34 × 10−48 5.44 (4.20, 7.05)
For comparison, the association of the human leukocyte antigen (HLA)-B*51 allele using a log-additive model of association, unadjusted (Punadj) and adjusted (Padj)
for gender, is shown at the bottom of the table. Nominally significant P-values are highlighted in bold and the respective odds ratios and 95% CI are indicated for
the adjusted model.
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abrogated (Padj = 9.39 × 10
−1), all pairwise conditional
associations remained significant even though the
strength of the association decreased substantially
(from 7.14 × 10−35 ≤ Padj ≤8.34 × 10
−48 to 1.84 × 10−17 ≤
Padj ≤5.42 × 10
−4). These results are consistent with the
low pairwise LD observed in the controls between these
two SNPs and the HLA-B*51 allele (r2 ≤ 0.59) (Table 4).
Phenotype-genotype relationships in Iranian BD patients
To investigate if the HLA-B*51 or the rs76546355/
rs116799036 risk allele status are associated with clinical
and demographic characteristics of Iranian BD patients,
we tested whether the characteristics have significantly
different frequencies among B*51-positive (66.7% or 454
out of 681 patients) and B*51-negative cases (33.3% or
227 out of 681 patients), or between (AA + GA) patients
when compared to GG patients (Table 5). The oral
aphthosis variable was not studied because this clinical
phenotype is present in virtually all BD patients. We
found that B*51 carriers have a higher risk of a positive
pathergy test reaction (P = 7.34 × 10−3, OR (95% CI) =
1.56 (1.13, 2.16)) and of a positive family history of BD
(P = 2.35 × 10−2, OR (95% CI) = 2.16 (1.09, 4.27)), but
these associations were not significant after Bonferroni
correction. Positivity for the risk allele at rs76546355/
rs116799036 (A) predominates in BD cases with genital
ulcers (P = 1.05 × 10−3, OR (95% CI) = 1.59 (1.20, 2.09)),Table 4 Pairwise linkage disequilibrium (LD) and conditional
HLA-B*51
Covariate rs76546355 rs284
Variant r2 Padj-values, OR (95% CI) r
2
rs76546355 - 0.59
rs2848713 9.39 × 10−1 -
HLA-B*51 1.78 × 10−8, 2.75 (1.93, 3.92)
LD values were computed in the control samples only. Nominally significant P-value
indicated. P-values were adjusted for gender and calculated in the subset of individpositive pathergy test (P = 2.31 × 10−4, OR (95% CI) =
1.69 (1.28, 2.23)) and positive BD family history (P =
1.59 × 10−3, OR (95% CI) = 2.52(1.40, 4.58), and these as-
sociations withstand Bonferroni correction.
Discussion
In this study, we confirmed in a large Iranian dataset that
B*51 is the HLA-B allele most strongly associated with in-
creased BD risk and we detected protective associations of
HLA-B*35, B*52 and B*40 alleles, which remain significant
after Bonferroni correction. Association of non-B*51 al-
leles (for example, B*27, B*35, B*44, B*52, B*56, B*57) has
been described mostly in isolated and underpowered re-
ports [2,20-23], and may result from small samples or
Type I errors secondary to the very large difference in
HLA-B*51 frequency between cases and controls. To re-
move that potential effect of B*51 on the remaining alleles,
we studied the genetic makeup of BD patients not carrying
the B*51 allele and found an association of the B*15 allele
only. B*15 has previously been reported to constitute a
risk factor for BD in the Moroccan population [1] and it
would be interesting to test if this allele accounts for BD
risk in populations where the B*51 prevalence is very low,
such as some African and Middle Eastern populations
[24,25]. The HLA-B*51 association with BD in Iranian has
been described previously [26,27], but the sample sizes
were smaller and the methods were different (for example,
serotyping versus genotyping).association results for rs76546355, rs2848713, and
8713 HLA-B*51
Padj-values, OR (95% CI) r
2 Padj-values, OR (95% CI)
5.63 × 10−14, 5.56 (3.52, 8.79) 0.58 1.24 × 10−7, 2.54 (1.79, 3.61)
0.35 5.42 × 10−4, 1.68 (1.25, 2.26)
1.84 × 10−17, 3.92 (2.83, 5.44) -
s are highlighted in bold and the respective odds ratio (OR) and 95% CI are
uals allelotyped for human leukocyte antigen (HLA)-B.
Table 5 Association of Behçet’s disease (BD) characteristics with human leukocyte antigen (HLA)-B*51 and rs76546355
HLA-B*51 rs76546355
Characteristic B*51+ B*51− P-values OR (95% CI) AA + GA GG P-values OR (95% CI)
Male sex, % 72.2 67.0 1.54 × 10−1 54.4 48.6 9.07 × 10−2
Age at onset, years, mean ± SD 26.3 ± 9.1 25.5 ± 10.2 3.02 × 10−1 26.0 ± 9.1 25.8 ± 10.4 7.25 × 10−1
Genital aphthosis, % 62.8 61.2 6.96 × 10−1 66.5 55.6 1.05 × 10−3 1.59[1.20-2.09]
Skin lesions, % 59.7 53.7 1.39 × 10−1 56.7 52.7 2.38 × 10−1
Ophthalmologic manifestations, % 63.0 62.1 8.23 × 10−1 59.2 61.6 4.88 × 10−1
Joint manifestations, % 33.9 28.2 1.31 × 10−1 32.0 28.9 3.32 × 10−1
Neurological manifestations, % 5.9 6.6 2.03 × 10−1 5.6 4.4 8.85 × 10−1
Vascular involvement, % 5.3 7.5 7.36 × 10−1 6.3 6.0 4.35 × 10−1
Gastrointestinal manifestations, % 3.3 3.1 8.79 × 10−1 3.6 4.4 5.28 × 10−1
Positive pathergy test, % 51.8 40.8 7.34 × 10−3 1.56 (1.13, 2.16) 50.2 37.5 2.31 × 10−4 1.69 (1.28, 2.23)
Positive family history of BD, % 10.3 5.1 2.35 × 10−2 2.16 (1.09, 4.27) 10.9 4.6 1.59 × 10−3 2.52 (1.40, 4.58)
The study of rs76546355 was performed in all BD patients (n = 973) while the HLA-B*51 study was conducted in the subset of patients allelotyped for HLA-B (n = 681, of
which 454 patients were positive for B*51 and the remaining 227 cases were B*51-negative). Significant P-values after Bonferroni correction (P ≤4.17 × 10−3) are
highlighted in bold. The odds ratio (OR) and 95% CI are indicated for nominally significant associations.
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across populations of various ethnicities in numerous
case-control association studies (reviewed and meta-
analyzed in de Menthon et al. [18]), there is limited un-
derstanding of the biological role of HLA-B*51 in the
pathogenesis of BD. Whether B*51 plays a role by itself,
or is in LD with another common genetic variant dir-
ectly involved in susceptibility to BD, has also been a
matter of intense debate. Among the top BD GWAS var-
iants tested here, we found that the rs76546355 SNP
(named rs116799036 in Hughes et al. [7]) is the MHC
polymorphism most associated with BD in an Iranian
dataset, at a similar level to the HLA-B*51 association.
To the best of our knowledge, the rs76546355/
rs116799036 association described here is the most
robust association ever reported with BD (unadjusted
P-value = 2.51 × 10−69). Interestingly, the allele frequencies
of rs76546355/rs116799036 in Iranian patients and con-
trols are very similar to the frequencies in the Turkish
cohort in Hughes et al. [7]. Very subtle ancestry differ-
ences can be detected in our dataset [28] but, as ob-
served previously, our findings of association are not
likely to be confounded by hidden population stratifica-
tion. rs76546355/rs116799036 is located in the promoter
region of HLA-B, approximately 24 kb upstream of
HLA-B and 18 kb upstream of MICA. Furthermore,
pairwise conditional analysis between HLA-B*51 and
rs76546355/rs116799036 in our dataset showed that
both variants remained associated after adjusting for the
effect of each other, although the strength of the associ-
ation decreased from 8.34 × 10−48 ≤ P ≤1.78 × 10−46 to
1.78 × 10−8 ≤ P ≤1.24 × 10−7. These results are consistent
with the similar frequencies observed in cases (0.388 and
0.391) and controls (0.126 and 0.121, respectively) butwith the low LD between these variants in Iranian (r2 =
0.58), and support the notion that rs76546355/
rs116799036 and HLA-B*51 are independent genetic risk
factors for BD in Iranians. These findings contrast with
those reported by Hughes et al. [7] who found that
rs116799036/rs76546355 remained associated when con-
ditioned on HLA-B*5101 in Turkish and Italian datasets
combined (P = 7.83 × 10−9), but the HLA-B*5101 associ-
ation with BD was completely abrogated by conditioning
on rs116799036/rs76546355 (P = 1.59 × 10−1). The dis-
crepancy between our results may derive from possible
differences between ethnicities and their haplotypic
structure in this genomic region, their originally much
stronger association of rs116799036/rs76546355 when
compared to that of HLA-B*5101 (P = 9.42 × 10−50 and
P = 4.37 × 10−28, respectively, in the meta-analysis) and
from the fact that their HLA alleles were imputed with
a four-digit resolution and not effectively genotyped [7].
Even though several high density SNP studies were con-
ducted for BD [4-7,19], the MHC region is extremely
polymorphic, and therefore we cannot formally exclude
the possibility that both HLA-B*51 and rs76546355/
rs116799036 are in LD with an as yet unidentified causal
variant that may be identified by deep sequencing.
Therefore, further studies to investigate the independ-
ence of these two genetic variants and the existence of
another causal variant are warranted.
We found that HLA-B*51 positivity is increased in pa-
tients with a positive pathergy test and a positive family
history, but these associations did not withstand Bonferroni
correction. Even though the family history was not tested
in previous B*51 genotype-phenotype correlations in
Iranian patients, these studies revealed a later age at onset
[29] and more ocular manifestations and positive pathergy
Xavier et al. Arthritis Research & Therapy  (2015) 17:81 Page 7 of 8tests [30] in B*51+ patients. A recent meta-analysis from
Maldini et al. [8] showed that HLA-B*51/B5 carriage pre-
dominates in males and is associated with moderately
higher prevalence of genital ulcers, ocular and skin mani-
festations, and a decreased prevalence of gastrointestinal
involvement. In their meta-analysis of 72 publications with
very diverse study characteristics (for example, sample size,
classification criteria, genotyping method), pathergy test
was not found associated with the presence of B*51 and
positive family history was not tested. Other studies have
reported that the HLA-B5 positivity is much more frequent
in familial BD than in sporadic cases [31]. Divergence be-
tween our nominally significant findings and those from
the Maldini et al. [8] meta-analysis may result from
between-study heterogeneity (for example, for eye involve-
ment) or publication bias (for example, for eye involvement
and male sex), but the lack of consistent associations in
Iranian studies and across different populations reinforces
the notion that the clinical and demographic characteristics
of B51-positive and B51-negative patients are virtually in-
distinguishable. We also found that positivity for the risk
allele at rs76546355/rs116799036 predominates in BD
cases with genital ulcers, positive pathergy test and positive
BD family history. Unfortunately, the association of two
SNPs (rs4947296 and rs4959053) described as the most
strongly associated with BD (1.80 × 10−26 ≤ P ≤4.01 × 10−13)
in GWAS conducted in Japanese, Korean and Han Chinese
[5,6,19] could not be assessed in this study.Conclusions
In conclusion, we found that the HLA-B*51 allele and the
rs76546355/rs116799036 MHC SNP are independent gen-
etic risk factors for BD in Iranians, and that positivity for
the rs76546355/rs116799036 risk allele, but not for the
B*51 allele, correlates with specific demographic charac-
teristics or clinical manifestations in BD patients. In the
near future, deep sequencing studies of the MHC locus in
large datasets of patients and controls are expected to
shed further light on the strongest BD genetic risk factors
in this complex chromosomal region.Additional file
Additional file 1: Table S1. Primer sequences used to genotype the
three single nucleotide polymorphisms (SNPs) investigated in this study.Abbreviations
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